A common antibiotic used to treat liver disease could give rise to an “almost untreatable” superbug, scientists warned in a new study. The antibiotic, rifaximin, has enabled the global emergence of ...
Rifaximin prophylaxis was no better than placebo at preventing deaths and other negative outcomes from spontaneous bacterial peritonitis (SBP) in patients with severe cirrhosis, according to interim ...
A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug. The international team of researchers found that an antibiotic commonly ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
When the liver fails, toxins—such as ammonia—that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results